Listen to the Latest ‘KFF Health News Minute’
kffhealthnews - The "KFF Health News Minute" brings original health care and health policy reporting from our newsroom to the airwaves each week.
AI Summary: A phase 2 study investigated FGFR inhibition with rogaratinib in succinate dehydrogenase–deficient gastrointestinal stromal tumors. Results reported tumor control in this rare molecular subset, offering a targeted therapeutic approach where options are sparse and validating FGFR as a biologic vulnerability in SDH‑deficient GIST.
Related Stories
Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 8 hrs
Adjuvant selpercatinib sharply cuts recurrence in RET‑fusion lung cancer / 5 wks
CRISPR CD33‑deleted allogeneic transplant shows early AML promise / 7 wks
Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 2 months
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 7 days
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 13 days
Some tumors kill neighboring healthy cells to fuel growth / 4 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Avian Influenza, Adolescent Health, Vaccine Safety, Neuroscience and look for the RSS link.
StackHealth Time Machine